MEK Mutation clinical trials at UCSF

1 research study open to eligible people

A MEK mutation is a change in a gene that helps control cell growth. UCSF is running early phase studies of oral drugs for people with solid tumors and MEK mutations. These studies test safety, dosing, and how the drug moves in the body in open label trials.

Showing trials for

  • NST-628 Oral Tablets in Subjects With Solid Tumors

    open to eligible people ages 18 years and up

    This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment options.

    San Francisco, California and other locations

Our lead scientists for MEK Mutation research studies include .

Last updated: